219 related articles for article (PubMed ID: 29694285)
1. Real-World Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy.
Deshpande CG; Kogut S; Willey C
J Manag Care Spec Pharm; 2018 May; 24(5):430-439. PubMed ID: 29694285
[TBL] [Abstract][Full Text] [Related]
2. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
Brown JD; Shewale AR; Talbert JC
J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
[TBL] [Abstract][Full Text] [Related]
3. Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants.
Deshpande CG; Kogut S; Laforge R; Willey C
Curr Med Res Opin; 2018 Jul; 34(7):1285-1292. PubMed ID: 29334815
[TBL] [Abstract][Full Text] [Related]
4. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
[TBL] [Abstract][Full Text] [Related]
5. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation.
Yao X; Abraham NS; Alexander GC; Crown W; Montori VM; Sangaralingham LR; Gersh BJ; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908412
[TBL] [Abstract][Full Text] [Related]
6. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.
Casciano JP; Dotiwala ZJ; Martin BC; Kwong WJ
J Manag Care Pharm; 2013 May; 19(4):302-16. PubMed ID: 23627576
[TBL] [Abstract][Full Text] [Related]
7. Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study.
Rome BN; Gagne JJ; Avorn J; Kesselheim AS
Am Heart J; 2021 Mar; 233():109-121. PubMed ID: 33358690
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study.
Gorst-Rasmussen A; Skjøth F; Larsen TB; Rasmussen LH; Lip GY; Lane DA
J Thromb Haemost; 2015 Apr; 13(4):495-504. PubMed ID: 25594442
[TBL] [Abstract][Full Text] [Related]
9. Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.
McHorney CA; Peterson ED; Ashton V; Laliberté F; Crivera C; Germain G; Sheikh N; Schein J; Lefebvre P
Curr Med Res Opin; 2019 Apr; 35(4):653-660. PubMed ID: 30265159
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of Japanese atrial fibrillation patients with poor medication adherence: A sub-analysis of the GENERAL study.
Akao M; Tsuji H; Kusano K; Matsui K; Hiramitsu S; Hatori Y; Odakura H; Ogawa H
J Cardiol; 2023 Feb; 81(2):209-214. PubMed ID: 35985869
[TBL] [Abstract][Full Text] [Related]
12. Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.
Kaatz S; Coleman CI; Bookhart B; Laliberté F; Nelson WW; Brown K; Martin S; Schein J; Lefebvre P
Curr Med Res Opin; 2018 Feb; 34(2):275-284. PubMed ID: 29164990
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases.
Degli Esposti L; Andretta M; Di Pasquale G; Gambera M; Saragoni S; Perrone V; Buda S
Vasc Health Risk Manag; 2019; 15():429-437. PubMed ID: 31632047
[TBL] [Abstract][Full Text] [Related]
14. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
[TBL] [Abstract][Full Text] [Related]
15. [Pharmaco-utilization and outcomes in patients treated with oral anticoagulants from 2014 to 2015: evidences from administrative databases of the Romagna Local Health Unit].
Degli Esposti L; Perrone V; Saragoni S; Buda S; Piovaccari G
G Ital Cardiol (Rome); 2020 Jan; 21(1):25-33. PubMed ID: 31960832
[TBL] [Abstract][Full Text] [Related]
16. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
[TBL] [Abstract][Full Text] [Related]
17. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Outcomes of Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation and Multiple Chronic Conditions: A Comparative Effectiveness Analysis.
Mentias A; Shantha G; Chaudhury P; Vaughan Sarrazin MS
JAMA Netw Open; 2018 Sep; 1(5):e182870. PubMed ID: 30646182
[TBL] [Abstract][Full Text] [Related]
19. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
[TBL] [Abstract][Full Text] [Related]
20. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
